NantCell, Inc. has entered into licensing agreement with GlobeImmune, Inc. for exclusive worldwide rights to the GlobeImmune's GI-4000 program, mutated Ras oncogene product. Under the agreement, GI-4000 will be evaluated in combination with multiple additional agents in patients with metastatic pancreas cancer, triple negative breast cancer (TNBC), ovarian cancer, urothelial cancer, head and neck squamous cell cancer, metastatic colorectal cancer and NSCLC, whose tumors express mutations in the Ras oncogene product. Concurrently, NantCell has entered into licensing agreement with GlobeImmune for exclusive rights to develop, manufacture and commercialize the GI-6207 and GI-6301. Concurrently, NantCell has exercised its option to enter into licensing agreement with GlobeImmune for GI-6100. Under the terms of the agreement, GlobeImmune is entitled to receive payments on the achievement of certain product development and commercialization milestones and royalties based on net sales of products by NantCell or its affiliates or sublicensees.